Health News Roundup: AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patients; Drug developer Servier's brain cancer drug slows tumor progession considerably

Following is a summary of current health news briefs.

AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patients

AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically removed, trial data showed. Tagrisso is already the crown jewel in the Anglo-Swedish drugmaker's portfolio, raking in $5.4 billion last year.

Drug developer Servier's brain cancer drug slows tumor progession considerably

Private drug developer Servier Group said on Sunday its experimental brain cancer treatment has considerably slowed the progession of a type of brain tumor, a positive in a field that has not seen progress for more than 20 years. The drug, vorasidenib, delayed the growth of grade 2 glioma for a median of 27.7 months, more than twice compared to 11.1 months for patients who received a placebo.